Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Biomarkers for optimizing the outcome of treatment with lenvatinib in patients with advanced hepatocellular carcinoma remain to be established despite intensive and comprehensive genomic research. Lenvatinib is characterized by its prominent inhibitory potency for fibroblast growth factor receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamauchi, Masami, Ono, Atsushi, Ishikawa, Akira, Kodama, Kenichiro, Uchikawa, Shinsuke, Hatooka, Haruna, Zhang, Peiyi, Teraoka, Yuji, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Hayes, Clair Nelson, Fujita, Masashi, Nakagawa, Hidewaki, Yasui, Wataru, Aikata, Hiroshi, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263646/
https://www.ncbi.nlm.nih.gov/pubmed/32677805
http://dx.doi.org/10.14309/ctg.0000000000000179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263646/
https://www.ncbi.nlm.nih.gov/pubmed/32677805
http://dx.doi.org/10.14309/ctg.0000000000000179

Ejemplares similares